In vivo selective monitoring of basal levels of cerebral dopamine using voltammetry with Nafion modified (NA-CRO) carbon fibre micro-electrodes.
The electrochemical technique of differential pulse voltammetry (DPV) with micro-biosensors has been used for a number of years to monitor in vivo and in situ changes in the extracellular concentration of cerebral ascorbic acid, as well as that of the metabolites of dopamine (DA) and serotonin (5-HT). We have recently prepared a carbon fibre micro-electrode (mCFE) which specifically pretreated and coated with Nafion (a negatively charged polymer which repels acids such as 3,4-dihydroxyphenylacetic acid (DOPAC)) allows the direct selective detection of the oxidation of DA and 5-HT in nanomolar concentration in vitro and that of extracellular basal levels of cerebral 5-HT in vivo (peak B at +240 mV). We describe here a modified version of this micro-biosensor now called NA-CRO mCFE as its active tip (30 microns in diameter) is coated with a 50/50 (v:v) mixture of Nafion and dibenzo-18-crown-6 (Aldrich). In vitro this newly reported electrode shows insensitivity to acids (e.g., DOPAC) up to 100 microns and sensitivity to 0.5-1 nM DA. In vivo, in the striatum of anaesthetised rats, a basal oxidation peak at +80 mV (peak A, on average 0.6 nA in height), which corresponds to the oxidation potential of DA in vitro, is consistently detectable with the NA-CRO mCFE (corresponding to an estimated concentration of 1.5 nM). Experiments performed in vivo in anaesthetised rats implanted in the striatum with uncoated (normal) mCFE to measure extracellular DOPAC or with NA-CRO mCFE have been performed in order to analyse the chemical nature of peak A in vivo. It is concluded that the addition of the crown-ether compound to the Nafion coat improves the sensitivity of the micro-biosensor for DA in vitro and allows the detection of its basal extracellular levels in vivo.
Crespi
F
F
Department of Physiology and Pharmacology, Medical School, Q.M.C., Nottingham, UK.
Möbius
C
C
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis; D000758:Anesthesia; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D003342:Corpus Striatum / Q000737:chemistry; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D005465:Fluorocarbon Polymers; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D008839:Microelectrodes; D010084:Oxidation-Reduction; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D013779:Tetrodotoxin / Q000494:pharmacology
D005465:Fluorocarbon Polymers; D015102:3,4-Dihydroxyphenylacetic Acid; C040402:perfluorosulfonic acid; D013779:Tetrodotoxin; D011189:Potassium Chloride; D006220:Haloperidol; D003913:Dextroamphetamine; D004298:Dopamine